Sudarshan Pharma Industries has announced the establishment of a fully owned subsidiary in Poland, marking a strategic milestone in the company's European market expansion plans. This development represents a significant step forward in the pharmaceutical company's international growth strategy.

Strategic European Expansion

The establishment of the Poland subsidiary demonstrates Sudarshan Pharma Industries' commitment to strengthening its presence in the European pharmaceutical market. Poland serves as a strategic location for accessing broader European markets and establishing a stronger foothold in the region.

Market Positioning

The Poland subsidiary positions Sudarshan Pharma Industries to better serve European customers and expand its pharmaceutical operations across the continent. This move aligns with the company's broader strategy to diversify its geographical presence and reduce dependence on domestic markets.

Business Implications

The establishment of this European subsidiary reflects the company's confidence in international market opportunities and its ability to execute cross-border expansion strategies. The Poland location provides access to European Union markets and regulatory frameworks, potentially facilitating broader regional growth initiatives.

This strategic development marks an important phase in Sudarshan Pharma Industries' evolution from a domestic-focused pharmaceutical company to one with international operations and market presence.

Sudarshan Pharma Industries Limited has successfully concluded its postal ballot process for the appointment of Dr. Vijay Ojha as Non-Executive Independent Director. The company announced the voting results on January 14, 2026, showing unanimous approval from participating shareholders.

Postal Ballot Results

The resolution for Dr. Vijay Ojha's appointment received overwhelming support from shareholders across all categories. The voting process, conducted entirely through electronic means via NSDL, concluded on January 13, 2026.

Director Appointment Details

Dr. Vijay Ojha was initially appointed as Additional Director (Non-Executive Independent) on October 18, 2025, based on the recommendation of the Nomination Remuneration Committee. The postal ballot sought formal shareholder approval for his appointment as Independent Director for a five-year term.

Professional Background and Committee Roles

Dr. Vijay Ojha brings over 30 years of industrial experience in the pharmaceutical sector, specifically in API and formulation development, scale-up commercialization. He holds a Doctorate of Philosophy (PhD) from Central Drug Research Institute, Lucknow. His professional experience includes associations with prominent pharmaceutical companies such as Lupin Limited, Sun Pharmaceuticals Limited, IPCA Laboratories Limited, and Flavine Inc., USA.

Upon appointment, Dr. Ojha will serve as a member of key board committees including the Stakeholders Relationship Committee and Nomination Remuneration Committee.

Voting Process Timeline

The company engaged National Securities Depository Limited (NSDL) to provide remote e-voting facility to shareholders. Mr. Vishal Manseta (Membership No.: 25183, COP No.: 8981), Company Secretary in Practice, served as Scrutinizer for conducting the postal ballot process.

The successful completion of the postal ballot process strengthens Sudarshan Pharma Industries' board composition with Dr. Ojha's extensive pharmaceutical industry expertise and compliance with corporate governance requirements.